M
Maria Domenica Cappellini
Researcher at University of Milan
Publications - 570
Citations - 21441
Maria Domenica Cappellini is an academic researcher from University of Milan. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 71, co-authored 518 publications receiving 18668 citations. Previous affiliations of Maria Domenica Cappellini include Centra & Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
Caterina Borgna-Pignatti,Simone Rugolotto,Piero De Stefano,Huaqing Zhao,Maria Domenica Cappellini,Giovanni Carlo Del Vecchio,Maria Antonietta Romeo,Gian Luca Forni,Maria Rita Gamberini,Roberta Ghilardi,Antonio Piga,Avital Cnaan +11 more
TL;DR: Survival and complication-free survival of patients with thalassemia major continue to improve, especially for female patients born shortly before or after the availability of iron chelation.
Journal ArticleDOI
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Maria Domenica Cappellini,Alan R. Cohen,Antonio Piga,Mohamed Bejaoui,Silverio Perrotta,Leyla Agaoglu,Yesim Aydinok,Antonis Kattamis,Yurdanur Kilinç,John B. Porter,Marcello Capra,Renzo Galanello,Slaheddine Fattoum,Guillermo Drelichman,Carmelo Magnano,Mônica Pinheiro de Almeida Veríssimo,Miranda Athanassiou-Metaxa,Patricia J. Giardina,Alexandra Kourakli-Symeonidis,Gritta Janka-Schaub,Thomas D. Coates,Christiane Vermylen,Nancy F. Olivieri,Isabelle Thuret,Herbert Opitz,C. Ressayre-Djaffer,Peter W. Marks,Daniele Alberti +27 more
TL;DR: A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.
Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
TL;DR: The third edition of the TIF guidelines was published by Musallam et al. as mentioned in this paper and includes updated information on new approaches for more effective, safe and less laborious treatment, and an overview of the progress achieved to date towards a total cure using methods such as gene therapy and stem cell transplantation.
Journal ArticleDOI
Survival and complications in thalassemia.
Caterina Borgna-Pignatti,Maria Domenica Cappellini,P. De Stefano,G. C. Del Vecchio,Gian Luca Forni,Maria Rita Gamberini,R. Ghilardi,Raffaella Origa,Antonio Piga,Maria Antonietta Romeo,Huaqing Zhao,Avital Cnaan +11 more
TL;DR: In conclusion, rates of survival and complication‐free survival continue to improve, due to better treatment strategies, and new complications are appearing in long‐term survivors.
Journal ArticleDOI
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Caterina Borgna-Pignatti,Maria Domenica Cappellini,Piero De Stefano,Giovanni Carlo Del Vecchio,Gian Luca Forni,Maria Rita Gamberini,Roberta Ghilardi,Antonio Piga,Maria Antonietta Romeo,Huaqing Zhao,Avital Cnaan +10 more
TL;DR: In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major, and the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferrediprone.